BMO Capital Maintains Outlook On ICON Public Limited Company (ICLR) After Management Call [Yahoo! Finance]
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
Icon (NASDAQ:ICLR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Icon (NASDAQ:ICLR) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.